07:00 , Mar 15, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity Cannabinoid CB1 receptor (CNR1) In vitro and rodent studies identified peripherally restricted CNR1 antagonists that could help treat metabolic diseases. In vitro,...
01:06 , Oct 14, 2011 |  BC Extra  |  Company News

Cancer Research Technology names Chambre chairman

Cancer Research U.K.'s commercial arm, Cancer Research Technology, appointed Peter Chambre chairman. He succeeds Melanie Lee, who has been chairman since 2003. Chambre is chairman of Xellia Pharmaceuticals A/S (Coppenhagen, Denmark) and 7TM Pharma A/S...
07:00 , Apr 14, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Obesity Neuropeptide Y receptor Y2 (NPY2R); NPY4R Studies in mice suggest that a lipidated peptide agonist of NPY2R and NPY4R could help treat obesity....
08:00 , Feb 7, 2011 |  BioCentury  |  Product Development

Obesity Reset

Even after FDA rejected the advice of its advisory committee and requested a cardiovascular outcomes trial of Orexigen Inc. 's Contrave bupropion/naltrexone to treat obesity, companies with earlier stage programs remain hopeful they will be...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Clinical News

TM38837: Phase I data

A double-blind, placebo-controlled, crossover, Dutch Phase I trial in 24 healthy volunteers showed that a single 500 mg dose of oral TM38837 attenuated the CNS effects of the CB1 agonist tetrahydrocannabinol (THC), including increases in...
07:00 , Aug 19, 2010 |  BC Innovations  |  Cover Story

Peripheral CNR1 antagonists to the fore

In the three years following an FDA panel recommendation against approval of sanofi-aventis Group 's Acomplia rimonabant to treat obesity due to severe neurological side effects, centrally acting inhibitors of cannabinoid CB 1 receptor have...
07:00 , Aug 5, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Obesity Cannabinoid CB1 receptor (CNR1) Mouse studies suggest that peripheral CNR1 blockade could help treat obesity and obesity-associated metabolic disorders. In two mouse models...
07:00 , Jun 7, 2010 |  BioCentury  |  Strategy

J&J's Pulmonary Push

In a pair of deals last week, Johnson & Johnson doubled the number of compounds in its disclosed pipeline for respiratory diseases from four to eight, and it sounds like the pharma is still shopping....
07:00 , Jun 3, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Metabolic disease

Metabolic disease Obesity Cannabinoid CB1 receptor (CNR1) A study in rodents suggests that the peptide hemopressin, a brain-derived inverse agonist of CNR1, could be useful for treating obesity. In rats, intraventricular injection of hemopressin reduced...
07:00 , May 31, 2010 |  BC Week In Review  |  Company News

7TM, J&J deal

7TM received an undisclosed milestone payment from Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals Inc. subsidiary under a 2005 discovery deal. The milestone was triggered by the selection of an undisclosed clinical candidate. This is the second...